Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

Next Previous
Trial Profile

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use

Most Recent Events

  • 22 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
  • 02 Dec 2014 Two treatment arms have been added.(Placebo single dose and Roflumilast 500µg single dose) as reported by ClinicalTrials.gov record.
  • 02 Dec 2014 Planned number of patients changed from 40 to 30 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top